Myriad Genetics Inc SEC filings MYGN
Myriad Genetics Inc has 1,002 filings in SEC EDGAR's recent list, going back to Aug 14, 2015. Its latest annual report, Form ARS, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 14, 2026 | — |
| DEF 14A | Proxy statement | Apr 14, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 9, 2025 | — |
| DEF 14A | Proxy statement | Apr 9, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 17, 2024 | — |
| DEF 14A | Proxy statement | Apr 17, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 12, 2023 | — |
| DEF 14A | Proxy statement | Apr 12, 2023 | — |
| PRE 14A | Preliminary proxy statement | Mar 30, 2023 | — |
| DEFA14A | Additional proxy material | Apr 14, 2022 | — |
| DEF 14A | Proxy statement | Apr 14, 2022 | Jun 2, 2022 |
| DEFA14A | Additional proxy material | Apr 15, 2021 | — |
| DEF 14A | Proxy statement | Apr 15, 2021 | Jun 3, 2021 |
| DEFA14A | Additional proxy material | Oct 15, 2020 | — |
| DEFA14A | Additional proxy material | Oct 15, 2020 | — |
| DEF 14A | Proxy statement | Oct 15, 2020 | Dec 4, 2020 |
| DEFA14A | Additional proxy material | Oct 16, 2019 | — |
| DEF 14A | Proxy statement | Oct 16, 2019 | Dec 5, 2019 |
| DEFA14A | Additional proxy material | Oct 10, 2018 | — |
| DEF 14A | Proxy statement | Oct 10, 2018 | Nov 29, 2018 |
| DEFA14A | Additional proxy material | Oct 12, 2017 | — |
| DEF 14A | Proxy statement | Oct 12, 2017 | Nov 30, 2017 |
| DEFA14A | Additional proxy material | Oct 11, 2016 | — |
| DEF 14A | Proxy statement | Oct 11, 2016 | Dec 1, 2016 |
| DEFA14A | Additional proxy material | Oct 15, 2015 | — |
| DEF 14A | Proxy statement | Oct 15, 2015 | Dec 3, 2015 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.